全文获取类型
收费全文 | 2118篇 |
免费 | 164篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 107篇 |
妇产科学 | 63篇 |
基础医学 | 278篇 |
口腔科学 | 17篇 |
临床医学 | 279篇 |
内科学 | 430篇 |
皮肤病学 | 72篇 |
神经病学 | 164篇 |
特种医学 | 44篇 |
外国民族医学 | 1篇 |
外科学 | 192篇 |
综合类 | 12篇 |
一般理论 | 2篇 |
预防医学 | 161篇 |
眼科学 | 44篇 |
药学 | 127篇 |
肿瘤学 | 284篇 |
出版年
2023年 | 20篇 |
2022年 | 25篇 |
2021年 | 50篇 |
2020年 | 35篇 |
2019年 | 59篇 |
2018年 | 70篇 |
2017年 | 39篇 |
2016年 | 52篇 |
2015年 | 63篇 |
2014年 | 68篇 |
2013年 | 87篇 |
2012年 | 140篇 |
2011年 | 130篇 |
2010年 | 72篇 |
2009年 | 69篇 |
2008年 | 99篇 |
2007年 | 134篇 |
2006年 | 110篇 |
2005年 | 99篇 |
2004年 | 110篇 |
2003年 | 96篇 |
2002年 | 104篇 |
2001年 | 53篇 |
2000年 | 38篇 |
1999年 | 47篇 |
1998年 | 25篇 |
1997年 | 24篇 |
1996年 | 19篇 |
1995年 | 13篇 |
1994年 | 12篇 |
1993年 | 19篇 |
1992年 | 31篇 |
1991年 | 26篇 |
1990年 | 14篇 |
1989年 | 18篇 |
1988年 | 20篇 |
1987年 | 27篇 |
1986年 | 21篇 |
1985年 | 17篇 |
1984年 | 16篇 |
1983年 | 11篇 |
1982年 | 8篇 |
1979年 | 12篇 |
1978年 | 4篇 |
1977年 | 6篇 |
1976年 | 6篇 |
1975年 | 7篇 |
1972年 | 5篇 |
1969年 | 6篇 |
1927年 | 4篇 |
排序方式: 共有2290条查询结果,搜索用时 15 毫秒
1.
Sherry X Yang Richard M Simon Antoinette R Tan Diana Nguyen Sandra M Swain 《Clinical cancer research》2005,11(17):6226-6232
PURPOSE: To delineate gene expression patterns and profile changes in metastatic tumor biopsies at baseline and 1 month after treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib in patients with metastatic breast cancer. EXPERIMENTAL DESIGN: Patients were treated with 150 mg of oral erlotinib daily. Gene expression profiles were measured with Affymetrix U133A GeneChip and immunohistochemistry was used to validate microarray findings. RESULTS: Estrogen receptor (ER) status by immunohistochemistry is nearly coincided with the two major expression clusters determined by expression of genes using unsupervised hierarchical clustering analysis. One of 10 patients had an EGFR-positive tumor detected by both microarray and immunohistochemistry. In this tumor, tissue inhibitor of metalloproteinases-3 and collagen type 1 alpha 2, which are the EGF-down-regulated growth repressors, were significantly increased by erlotinib. Gene changes in EGFR-negative tumors are those of G-protein-linked and cell surface receptor-linked signaling. Gene ontology comparison analysis pretreatment and posttreatment in EGFR-negative tumors revealed biological process categories that have more genes differentially expressed than expected by chance. Among 495 gene ontology categories, the significant differed gene ontology groups include G-protein-coupled receptor protein signaling (34 genes, P = 0.002) and cell surface receptor-linked signal transduction (74 genes, P = 0.007). CONCLUSIONS: ER status reflects the major difference in gene expression pattern in metastatic breast cancer. Erlotinib had effects on genes of EGFR signaling pathway in the EGFR-positive tumor and on gene ontology biological process categories or genes that have function in signal transduction in EGFR-negative tumors. 相似文献
2.
The routine manual encoding of pathological data, using the SNOP and SNOMED systems at two London teaching hospitals, was reviewed. The error rates in the two departments were compared and the causes analysed. The relative merits of SNOP and SNOMED were considered. Methods to optimise the efficiency of manual encoding are suggested and the importance of accuracy in coding is emphasised. 相似文献
3.
Scarlett Lin Gomez Cynthia D O'Malley Antoinette Stroup Sarah J Shema William A Satariano 《BMC cancer》2007,7(1):193
Background
Colorectal cancer, if detected early, has greater than 90% 5-year survival. However, survival has been shown to vary across racial/ethnic groups in the United States, despite the availability of early detection methods. 相似文献4.
5.
6.
7.
Alex L. van Bemmel Rutger H. van den Hoofdakker Domien G. M. Beersma Antoinette L. Bouhuys 《Psychopharmacology》1993,113(2):225-230
Drug-induced improvement of depression may be mediated by changes in sleep physiology. The aim of this study was to relate changes in sleep polygraphic variables to clinical state during treatment with citalopram, a highly specific serotonin uptake inhibitor. Sixteen patients took part. The study was single-blind and uncontrolled. A 1-week wash-out period was followed by 1 week of placebo administration, a medication period of 5 weeks, and a 1-week placebo period. For the entire group a significant decrease of rapid eye movement sleep (REMS) and a significant lengthening of REMS latency were observed initially as well as at the end of treatment. No changes in sleep continuity were found, but non-REMS stage 2 (percentage) was significantly increased. On the basis of clinical change, as expressed by the scores of the Hamilton Rating Scale for Depression, at the end of the citalopram treatment the patient group was split in two halves: eight less and eight more improved patients. The groups did not differ with respect to any sleep polygraphic varible. 相似文献
8.
9.
Les rétinopathies vasculaires peuvent être accompagnées d'une modification de la forme des vaisseaux. Les patients atteints courent le risque de perdre la vue. Jusqu'ici, les méthodes utilisées par les ophthalmologistes pour analyser ces modifications sont qualitatives. Nous proposons une méthode nouvelle d'analyse de la tortuosité des vaisseaux de la rétine en vue d'élaborer par la suite un outil d'aide au diagnostic des rétinopathies vasculaires. La première étape de la méthode est une représentation symbolique de la structure vasculaire de la rétine. La deuxième étape appelée reconstitution 2D est la classification des entités vasculaires en gros vaisseaux (artères ou veines) et en petits vaisseaux (artérioles ou veinules) en utilisant la moyenne du diamèetre et du niveau de gris des segments de vaisseau comme paramètres discriminants. La dernière étape consiste à calculer l'excentricité des vaisseaux pour décrire leur tortuosité. Pour s'assurer de la capacité de l'excentricitéà décrire les petites modifications de forme, un second paramètre a été défini à titre comparatif. Les résultats obtenus permettent de quantifier les modifications de forme des vaisseaux. 相似文献
10.
Antoinette MaassenVanDenBrink MSc ; Monique N. Vergouwe MSc ; Roel A. Ophoff PhD ; Pramod R. Saxena MD PhD ; Michel D. Ferrari MD PhD ; Rune R. Frants PhD 《Headache》1998,38(4):288-291
The 5-HT1 receptor agonist, sumatriptan, is highly effective in the treatment of migraine. Some patients, however, do not respond or experience recurrence of the headache. In addition, some patients report chest symptoms after sumatriptan. We investigated whether these different responses could be attributed to genetic diversity of the 5-HT1B receptor, which most likely mediates the therapeutic action and the coronary side effects of sumatriptan. Allele frequencies of two polymorphisms in the 5-HT1B receptor gene ( G861C and T-261G ) were investigated in migraine patients with consistently good response to sumatriptan (n=14), with no response (n=12), with recurrence of the headache (n=12), with chest symptoms (n=13), and in patients without chest symptoms (n=27). Allele frequencies (G:0.74; C:0.26 at nt 861 and T:0.39; G:0.61 at nt -261) did not differ between patient groups, indicating that genetic diversity of the 5-HT1B receptor does not seem to be involved in the different clinical responses to sumatriptan. 相似文献